Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MiddleBrook Pharmaceuticals, Inc logo — company profile

MiddleBrook Pharmaceuticals, Inc

Founded 2000 United States Westlake, United States 26 employees Post-IPO Equity Total: $110.00M Biotechnology, Pharmaceutical

General Information

Company Name MiddleBrook Pharmaceuticals, Inc
Founded Year 2000
Location United States Westlake, United States
Employees 26
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with MiddleBrook Pharmaceuticals, Inc. To contact MiddleBrook Pharmaceuticals, Inc, visit middlebrookpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About MiddleBrook Pharmaceuticals, Inc

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a biotechnology and pharmaceutical company founded in 2000 in the United States. The company is focused on addressing unmet medical needs by developing and commercializing anti-infective products. MiddleBrook's current product portfolio includes KEFLEX®, the immediate-release brand of cephalexin, and MOXATAG®, which is the first and only FDA-approved once-daily amoxicillin. The company's last significant investment was a $100.00M Post-IPO Equity investment on 02 July 2008, which was made by Equity Group Investments. This investment reflects confidence in MiddleBrook Pharmaceuticals' potential for growth and expansion in the pharmaceutical industry. With a focus on addressing critical medical needs and a track record of FDA-approved products, MiddleBrook Pharmaceuticals, Inc. represents an attractive opportunity for venture capital investment in the biotechnology and pharmaceutical sectors.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $100.00M 1
Equity Group Investments
Equity Group Investments
02 Jul 2008
Post IPO Equity $10.00M 1
Deerfield
01 Nov 2007

MiddleBrook Pharmaceuticals, Inc Alternatives & Competitors

View All Alternatives
MiddleBrook Pharmaceuticals, Inc vs
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals

Delivering Innovation to the Eye™ NOW HIRING!

Post-IPO Equity
190 employees
Biotechnology, Health Care
MiddleBrook Pharmaceuticals, Inc vs
TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. United States

TNF Pharmaceuticals is a clinical stage pharmaceutical company committed to extending a healthy life...

Post-IPO Equity
10 employees
Biotechnology, Pharmaceutical
MiddleBrook Pharmaceuticals, Inc vs
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. United States

Bringing life-changing therapeutics to China and the world.

Post-IPO Equity
44 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About MiddleBrook Pharmaceuticals, Inc

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) (formerly Advancis) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. MiddleBrook currently markets KEFLEX®, the immediate-release brand of cephalexin, and MOXATAG® – the fi...
MiddleBrook Pharmaceuticals, Inc was founded in 2000.
MiddleBrook Pharmaceuticals, Inc is headquartered in Westlake, United States.
MiddleBrook Pharmaceuticals, Inc operates in Biotechnology and Pharmaceutical.
MiddleBrook Pharmaceuticals, Inc has approximately 26 employees.
MiddleBrook Pharmaceuticals, Inc has completed 2 funding rounds, raising a total of $110.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to MiddleBrook Pharmaceuticals, Inc include EyePoint Pharmaceuticals, TNF Pharmaceuticals, Inc., CASI Pharmaceuticals, Inc., Aquavit Pharmaceuticals, Inc, Nevakar Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MiddleBrook Pharmaceuticals, Inc and EyePoint Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MiddleBrook Pharmaceuticals, Inc, https://bouncewatch.com/company/middlebrook-pharmaceuticals-inc, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes